London Area, United Kingdom
Bio-pharmaceutical and healthcare CEO/Board member and thought-leader with an impressive track record of building and managing early stage Life Sciences & MedTech companies through shaping, restructuring, capital raising to positioning for IPO (AIM/ NASDAQ/ OTC listing). Boasts 30 years international experience in the US and UK, in General Management, Marketing, Sales, Business Development, Strategic Marketing and M&A. A corporate strategist and visionary who offers a deep knowledge of the pharmaceutical / biotech sector with sharp transatlantic finance acumen. Skills Overview: • Healthcare, Life Science & Medtech Thought Leader • Early stage to IPO: AIM / OTC / NASDAQ • Capital Raising: Extensive Public Markets, Private Equity & VC • Extensive Wall Street Mid-Tier Healthcare Banking Networks • Experienced Board Member & Sub-Committee Member • Deal Origination, Shaping & Execution • Building companies through Mergers & Acquisitions • Creation / Leadership of Future Growth Strategies • General Management with Robust P&L Control • Board Building & C-Level Talent Recruitment • Corporate Governance & Infrastructure Implementation • Organisational Restructuring & Evolution
Life science therapeutic company focused developing cures for unmet needs such as sepsis, autoimmune diseases, CNS indications and organ recovery for transplantation. The patent protected novel extracorporeal therapeutic device has received US FDA breakthrough designation for sepsis and systematic lupus erythematosus (SLE). Santersus is currently running clinical trials for Sepsis, Alzheimer's, SLE, and liver recovery (reperfusion) prior to transplant. Closed Series A raise with Terumo Corp (one of the world's largest medtech company) leading the round.
Importer and distributor of orphan and rare disease drugs across Europe and the Middle East, including the paediatric life-saving gene therapy, Libmeldy. Wellford-Therismos is Europe's leading medicinal cannabis company with production and processing in Canada (via M&A) and importation and distribution in the UK and Germany where Wellford has a category growth partnership with Walgreens Boots Alliance. Raised over £40M from private investors. The Company also built the leading Wellness brand in the UK, Cannaray Ltd. This business was separated from Wellford creating two companies in order to maximise value for our shareholders, resulting in shares in both companies. My dog, Bozy, was given a death sentence in August 2018 as a 9 month old puppy. Cannabis saved his life and is the reason for building a company in this sector. We have made four M&A deals to establish a leading presence in Europe with sales in excess of $80M and 130 employees across Canada, UK and Germany.
Co-Founded the business and led fund raising initiatives to grow the business to be the second largest private provider of dialysis services in the UK; boasting 26 clinics treating 2,500 patients. Company was sold to DaVita Inc (the world's second largest provider of dialysis services) resulting in the private equity group, BGF, achieving one of the highest returns on investment in the history of the fund.
Evolved the business from start-up, managing clinical development in the US, EU & other countries to develop 200+ granted patent and global Phase 2 clinical trials. Listing on NASDAQ as the Chairman and CEO November 2016. Led successful listing on NASDAQ November 2016, ticker XBIO, and relocating the Company from the UK to Boston USA. Originated, negotiated and executed license transactions in excess of $200M. Built a talented, credible executive team, board and SAB, and led outreach efforts at conferences and on Wall Street with key mid-tier Life Science banks to successfully raise $60 million capital in public markets.
Co-Founded the Corporate Finance & M&A boutique focused towards the healthcare sector. Milestones include: • Led US$multi-million above-value sale of the world’s largest continuous passive motion device Co. • Advisor to private British Silicone implant manufacturer on sale to US public company. • Divided and sold a major Eastern European pharmaceutical company. • Brokered sale of a Medical Systems spin out to a private French Interventional Cardiology Co.